Predictors of Unfavorable Outcomes in Patients with Atrial Fibrillation and Concomitant Heart Failure with Different Ejection Fractions: RIF-CHF Register One-Year Follow-Up

Table 8

Univariate regression logistic analysis of the risk of myocardial infarction.

Group of factors	Factor	AF-HFpEF		AF-HFmrEF		AF-HFrEF
		OR (2.5–97.5)	value	OR (2.5–97.5)	value	OR (2.5–97.5)	value
Laboratory tests	LDH	1.006 (1.002–1.01)	0.004	1.007 (1.001–1.014)	0.046
	Triglycerides					1.566 (1.11–2.362)	0.02
Demography	Age> 65 years	3.115 (1.044–13.398)	0.071	3.27 (1.099–12.063)	0.047
Habits and lifestyle	Level of physical activity	0.455 (0.173–1.069)	0.086
	Unbalanced diet					4.714 (1.363–29.721)	0.038
Symptoms and syndromes	Signs of arterial hypertension (accent of the second tone on the pulmonary artery and left ventricular hypertrophy)	3.242 (1.269–9.964)	0.022	10.108 (1.969–185.253)	0.027
	Anemia					1.964 (0.84–4.21)	0.097
	The number of specific signs of HF (pressure in the jugular veins, gallop rhythm, mixing the top of the jolt, wheezing in the lungs, and congestion in the lungs)	1.87 (1.256–2.754)	0.002	1.962 (1.237–3.208)	0.005
Concomitant diseases	Abnormal liver function			4.417 (1.34–13.764)	0.011
CV system characteristics	Aortic valve insufficiency	0.418 (0.148–1.045)	0.082	7.368 (2.457–27.37)	0.001	3.427 (1.565–7.683)	0.002
	Vascular disease	8.226 (3.029–28.777)	<0.001
	ECG abnormalities			10.88 (2.92–70.815)	0.002
	History of infarction and/or stroke	9.643 (3.547–33.762)	<0.001
	History of cardiomyopathy	1.591 (0.827–2.635)	0.096	1.68 (0.88–2.999)	0.086	1.528 (0.947–2.371)	0.068
	Pulmonary insufficiency	6.283 (2.553–17.746)	<0.001	2.632 (0.963–7.412)	0.06	0.499 (0.248–0.948)	0.041
	Right atrium enlargement			2.632 (0.963–7.412)	0.06	0.499 (0.248–0.948)	0.041
	Family history of early ischemic heart disease			0.256 (0.039–0.972)	0.08	1.911 (1.009–3.569)	0.044
	Hemodynamically significant coronary artery stenosis			3.316 (1.1–9.569)	0.028	2.036 (1.025–3.888)	0.035
	History of coronary arteries stenting	3.311 (1.131–8.591)	0.019	4.727 (1.528–14.174)	0.006	2.043 (0.99–4.011)	0.044
	Thromboembolism of pulmonary artery	5.873 (0.809–29.014)	0.041	5.7 (1.041–28.378)	0.032
	Degree of tricuspid insufficiency					1.601 (1.105–2.323)	0.013
	Venous thrombosis of the lower extremities	4.543 (0.966–16.216)	0.03	9 (0.76–127.873)	0.078
	Echocardiographic signs of myocardial infarct (cicatricial changes and local conduction disturbance zones)	9.509 (3.986–24.457)	<0.001	10.51 (2.822–68.395)	0.002	4.459 (2.144–10.482)	<0.001
	Enlarged pulmonary trunk	4.165 (1.47–11.651)	0.006	9.797 (2.931–39.334)	<0.001	2.727 (1.323–5.652)	0.006
Therapy	Regular use of rivaroxaban			0.114 (0.006–0.79)	0.057
	Regular use of digoxin			0.324 (0.072–1.051)	0.088
	Regular use of ACE inhibitors			0.407 (0.147–1.158)	0.084
	Regular use of ivabradin					6.313 (1.516–24.687)	0.007
AF/HF features	HF developed after AF debut	3.154 (1.026–11.799)	0.058			0.471 (0.19–1.101)	0.089
	Age of HF debut	1.051 (1.005–1.101)	0.033	1.045 (0.996–1.102)	0.082
	Persistent form of AF					0.158 (0.009–0.752)	0.071
	Heart rate at rest			0.382 (0.143–0.945)	0.043
Scales and risks	CHA2DS2-VASc	1.372 (1.077–1.752)	0.01	1.398 (1.069–1.865)	0.017
	HAS-BLED			1.609 (1.09–2.432)	0.019